Literature DB >> 10445025

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

P R Meyer1, S E Matsuura, A M Mian, A G So, W A Scott.   

Abstract

Mutations in HIV-1 reverse transcriptase (RT) give rise to 3'-azido-3'-deoxythymidine (AZT) resistance by a mechanism that has not been previously reproduced in vitro. We show that mutant RT has increased ability to remove AZTMP from blocked primers through a nucleotide-dependent reaction, producing dinucleoside polyphosphate and extendible primer. In the presence of physiological concentrations of ATP, mutant RT extended 12% to 15% of primers past multiple AZTMP termination sites versus less than 0.5% for wild type. Although mutant RT also unblocked ddAMP-terminated primers more efficiently than wild-type RT, the removal of ddAMP was effectively inhibited by the next complementary dNTP (IC50 approximately equal to 12 microM). In contrast, the removal of AZTMP was not inhibited by dNTPs except at nonphysiological concentrations (IC50 > 200 microM).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10445025     DOI: 10.1016/s1097-2765(00)80185-9

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  155 in total

1.  Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.

Authors:  J Lennerstrand; D K Stammers; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antiviral Res       Date:  2012-06-01       Impact factor: 5.970

3.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

5.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

6.  The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.

Authors:  Matthew M Schuckmann; Bruno Marchand; Atsuko Hachiya; Eiichi N Kodama; Karen A Kirby; Kamalendra Singh; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2010-09-27       Impact factor: 5.157

7.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

Review 8.  HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy.

Authors:  Luis M Agosto; Pradeep D Uchil; Walther Mothes
Journal:  Trends Microbiol       Date:  2015-03-09       Impact factor: 17.079

9.  Fidelity of Dpo4: effect of metal ions, nucleotide selection and pyrophosphorolysis.

Authors:  Alexandra Vaisman; Hong Ling; Roger Woodgate; Wei Yang
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

10.  HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Paul L Boyer; Stephen H Hughes; John M Coffin; Abhay Jere; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.